Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-04-19
1999-12-07
Chan, Christina Y.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530331, 530351, 53038823, 5303892, 424 851, 4241451, 4241581, A61K 3800
Patent
active
059983787
ABSTRACT:
Compounds having proteolytic inhibitory activity useful for treating diseases, particularly as applied to the treatment of sepsis, AIDS or autoimmune diseases, resulting from a decrease in the circulating level of mature protein hormones derived from the proteolytic cleavage of prohormone precursors such as 26 kDProTNF, and methods for identifying compounds having the desired inhibitory activity are provided.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4495285 (1985-01-01), Shimizu et al.
patent: 4582788 (1986-04-01), Ehrlich
patent: 4596822 (1986-06-01), Powers et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4677063 (1987-06-01), Mark et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4699904 (1987-10-01), Doherty et al.
patent: 4704692 (1987-11-01), Ladner
patent: 4711886 (1987-12-01), Finke et al.
patent: 4717722 (1988-01-01), Doherty et al.
patent: 4766106 (1988-08-01), Katre et al.
patent: 4797396 (1989-01-01), Finke et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4829054 (1989-05-01), Emerson et al.
patent: 4923807 (1990-05-01), Webb et al.
patent: 4968614 (1990-11-01), Takiguchi et al.
patent: 5091303 (1992-02-01), Arnaout et al.
patent: 5109018 (1992-04-01), Powers et al.
patent: 5124147 (1992-06-01), Wissner et al.
patent: 5128258 (1992-07-01), Klostergaard
patent: 5136021 (1992-08-01), Dembinski et al.
patent: 5180819 (1993-01-01), Cayre et al.
patent: 5200333 (1993-04-01), Wilson
patent: 5247070 (1993-09-01), Yamamada et al.
Abstract, Dialog Accession No. 06706182, Medline Accession No. 89008182, Oshawa F. et al.: "Selective degradation of tumor necrosis factor in sensitive cells, and production of membrane-active substance"; and J. Biochem. (Tokyo) (Japan) (Apr. 1988) 103(4): 730-4.
Williams et al., "Epitope on Proteinase-3 Recognized by Antibodies from Patients with Wegener's Granulomatosis," J. of Immunol., 152:4722-4737 (1994).
Witko-Sarsat et al., "Expression of Recombinant Proteinase 3--Implication for its Role as Autoantigen," Clin. Exp. Immunol., 101:40 (1995) (Abstract 23).
Zimmer et al., "Three Human Elastase-Like Genes Corrdinately Expressed in the Myelomonocyte Lineage are Organized as a Small Genetic Locus on 19pter," Proc. Nat'l Acad. Sci., USA, 89:8215-8219 (Sep., 1992).
Ludemann et al., "Anti-Neutrophil Cytoplasm Antibodies in Wegener's Granulomatosis Recognize an Elastinolytic Enzyme," J. Exp. Med., 171:357-362 (Jan., 1990).
Ludemann et al., "Detection and Quantitation of Anti-meutrophil Cytoplasm Antibodies in Wegener's Granulomatosis by ELISA Using Affinity-purified Antigen," J. Immun. Meth., 114:167-174 (1988).
Maiorella et al., "Large-Scale Insect Cell-Culture for Recombinant Protein Production," Bio/Technology, 6:1406-1410 (Dec., 1988).
Marks et al., "Enkephalin Analogs as Substrates for the Assay of Brain Cysteine Proteinase (Cathepsin L) and its Endogenous Inhibitors," Peptides, 10:391-394 (1989).
McGuire et al., "Generation of Active Myeloid and Lymphoid Granule Serine Proteases Requires Processing of the Granule Thiol Protease Dipeptidyl Peptidase I," J. Biol. Chem., 268(4):2458-2467 (Feb. 5, 1993).
Merril et al., "Interleukin-1 and Tumor Necrosis Factor .alpha. Can Be Induced from Mononuclear Phagocytes by Human Immunodeficiency Virus Type 1 Binding to the CD4 Receptor," J. Virol., 63(10):4404-4408 (Oct., 1989).
Mohler et al., "Protection Against a Lethal Dose of Endotoxin by an Inhibitor of Tumour Necrosis Factor Processing," Nature, 370:218-220 (Jul. 21, 1994).
Mullis et al., "Specfic Enzymatic Amplification of DNA In Vitro: The Polymerase Chain Reaction," Cold Spring Harbor Symposium Quant. Biol., Cold Spring Harbor Laboratory, vol. LI, pp. 263-273 (1986).
Muller et al., "Synthesis and maturation of recombinant human tumor necrosis factor in eukaryotic systems," FEBS 3424, 197(1,2):99-104 (Mar., 1986).
Muller-Berat et al., "The Phylogeny of Proteinase 3/Myleoblastin, and Myeloperoxidase as Shown by Immunohistochemical Studies on Human Leukemic Cell Lines," Clin. Exp. Immunol., 93:24 (1993) (Abstract 31).
Munemitsu et al., "Molecular Cloning and Expression of a G25K cDNA, the Human Homolog of the Yeast Cell Cycle Gene CDC42," Mol. Cell. Biol., 10(11):5977-5982 (Nov., 1988).
Niles et al., "Wegener's Granulomatosis Autoantigen is a Novel Neutrophil serine Proteinase," Blood, 74(6):1888-1893 (Nov. 1, 1989).
Nowotny et al., "Preparation and Activity Measurements of Deuterated 50S Subunits for Neuron-Scattering Analysis," Methods in Enzymology, 164:131-147 (1988).
Olsen et al., "High-Efficiency Oligonucleotide-Directed Plasmid Mutagenesis," Proc. Nat'l Acad. Sci., USA, 87:1451-1455 (Feb., 1990).
Poli et al., "Tumor Necrosis Factor .alpha. Functions in an Autocrine Manner in the Induction of Human Immunodeficiency Virus Expression," Proc. Nat'l Acad. Sci., USA, 87:782-785 (Jan., 1990).
Robache-Gallea et al., "In Vitro Processing of Human Tumor Necrosis Factor-.alpha.," J. Biol. Chem., 270(40):23688-23692 (Oct. 6, 1995).
Salvesen et al., "An Unusual Specificity in the Activation of Neutrophil Serine Proteinase Zymogens," Biochem., 29:5304-5308 (1990).
Salvesen et al., "Zymogen Activation Specificity and Genomic Structure of Human Neutrophil Elastase and Cathepsin G Reveal a New Branch of the Chymotrypsinogen Superfamily of Serine Proteinases," Biomed. Biochim. Acta, 50:665-671 (1991).
Savige et al., "Anti-Neutrophil Cytoplasmic Antibodies (ANCA): Their Detection and Significance: Report from Workshops," Pathology, 26:186-193 (1994).
Seckinger et al., "A Human Inhibitor of Tumor Necrosis Factor .alpha.," J. Exp. Med. 167:1511-1516 (Apr., 1988).
Smith et al., "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector," Mol. Cell. Biol., 3(12)2156-2165 (Dec., 1983).
Streiter et al., "Cellular and Molecular Regulation of Tumor Necrosis Factor-Alpha Production by Pentoxifylline," Bioch. Biophys. Res. Comm., 155(3):1230-1236 (Sep. 30, 1988).
Sturrock et al., "Structure, Chromosomal Assignment, and Expression of the Gene for Proteinase-3," J. Biol. Chem., 267(29):21193-21199 (Oct. 15, 1992).
Summers and Smith, A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agrigultural Experiment Station, Bulletin No. 1555, pp. 1-56 (May, 1987).
Takahashi et al., "Structure of the Human Neutrophil Elastase Gene," J. Biol. Chem., 263(29):14739-14747 (Oct. 15, 1988).
Takebe et al., "SR.alpha. Promoter: an Efficient and Versatile Mammalian cDNA Expression System Composed of the Simian Virus 40 Early Promoter and the R-U5 Segment of Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat," Mol. Cell Biol., 8(1):466-472 (Jan., 1988).
Urata et al., "Dipeptide Processing Activates Recombinant Human Prochymase," J. Biol. Chem., 268(32):24318-24322 (Nov. 15, 1993).
White and Littman, "Viral Receptors of the Immunoglobulin Superfamily," Cell, 56:725-728 (Mar. 10, 1989).
Fazely et al., "Pentoxifylline (Trental) Decreases the Replication of the Human Immunodeficiency Virus Type I in Human Peripheral Blood Mononuclear Cells and in Cultured T Cells," Blood, 77(8):1653-1656 (Apr. 15, 1991).
Fiers, W., "Tumor Necrosis Factor: Characterization at the Molecular, Cellular and In Vivo Level," FEB 09976, 285(2):199-212 (Jul., 1991).
Gabay et al., "Antibiotic Proteins of Human Polymorphonuclear Leukocytes," Proc Nat'l Acad, Sci, USA, 86:5610-5614 (Jul., 1989).
Goodwin et al., "Molecular and Biological Characterization of a Ligand for CD27 Defines a New Family of Cytokines with Homology to Tumor Necrosis Factor," Cell, 73:447-456 (May 7, 1993).
Graf et al., "Cloning of TRAP, a Ligand for CD40 on Human T Cells," Eur. J. Immunol., 22:3191-3194 (1992).
Gupta et al., "Identity of Wegener's Autoantigen (P29) with Proteinase 3 and Myeloblastin," Blood, 76(10):2162 (Nov. 15, 1990).
Hagen, E.C., "Standardisation of ANCA Assays Using Purified Proteinase-3 (PR-3) and Myeloperoxidase (MPO)," Clin. Exp. Immunol., 101:41 (1995) (Abstract 27).
Hinshaw et al., "Survival of Primates in LD.sub.100 Septic Sh
Halenbeck Robert F.
Jewell David A.
Koths Kirston E.
Kriegler Michael
Perez Carl
Blackburn Robert P.
Chan Christina Y.
Chiron Corporation
Morley Kimberlin L.
Nolan Patrick J.
LandOfFree
Compositions for the inhibition of TNF hormone formation and use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for the inhibition of TNF hormone formation and use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for the inhibition of TNF hormone formation and use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-823820